Side Effects of Linzess (Linaclotide)
Diarrhea is the most common side effect of Linzess, occurring in a dose-dependent manner and sometimes becoming severe enough to require discontinuation, though this is relatively uncommon. 1
Most Common Side Effects
According to the FDA label and high-quality clinical guidelines, the primary adverse effects include 1:
Gastrointestinal Effects (Most Frequent)
Diarrhea - The predominant side effect
- Typically begins within the first 2 weeks of treatment
- Usually mild to moderate in severity (90.5% of cases) 2
- Led to discontinuation in only 4.0% of patients in clinical trials vs 0.3% for placebo 3
- Patients are 3 times more likely to discontinue due to diarrhea compared to placebo (RR 3.35), translating to 83 more per 1,000 patients 3
- Stop the medication immediately and contact your doctor if severe diarrhea develops 1
Gas (flatulence)
Abdominal pain - reported in 9.4% of patients 4
Abdominal bloating/distention - reported in 9.2% of patients 4
Nausea/vomiting - reported in 3.1% of patients 4
Serious Adverse Events
The 2023 AGA/ACG guidelines note that serious adverse events were rare and similar across treatment groups, with no serious adverse events of diarrhea reported in pooled analyses 3, 2. However, the certainty of evidence for serious adverse events was rated as low due to very serious imprecision 3.
Critical Warning Signs
Seek emergency care immediately if you develop 1:
- Unusual or severe abdominal pain
- Bright red, bloody stools
- Black stools that look like tar
Clinical Context from Real-World Evidence
A 2025 post-marketing analysis of the FDA Adverse Event Reporting System revealed novel safety concerns 4:
- Potential for clinically significant dehydration from linaclotide-induced diarrhea
- This represents an important real-world finding not prominently featured in clinical trials
Discontinuation Rates
Long-term safety data from pooled Phase 3 trials showed 2:
- 6.9% of linaclotide patients discontinued due to any adverse event (vs 3.0% placebo)
- 4.0% discontinued specifically due to diarrhea (vs 0.3% placebo)
- In long-term studies (up to 104 weeks), 9.4% discontinued due to any adverse event and 3.8% due to diarrhea
- Importantly, the most common reasons for discontinuation over the first year were loss of efficacy and insurance coverage barriers, NOT adverse events 3
Dose-Dependent Effects
The frequency of diarrhea varies by dose 5:
- 72 μg dose: 2.4% discontinued due to diarrhea
- 145 μg dose: 3.2% discontinued due to diarrhea
- 290 μg dose (approved for IBS-C): Similar pattern maintained
Important Safety Considerations
Contraindications
- Known or suspected mechanical GI obstruction 3
- Pediatric patients under 6 years of age (risk of serious dehydration)
Administration Guidance to Minimize Side Effects
- Take on an empty stomach, at least 30 minutes before the first meal of the day 3
- This timing may help reduce the severity of gastrointestinal side effects
Overall Safety Profile
The 2023 AGA/ACG guidelines rated the overall certainty of evidence for linaclotide as moderate, with high certainty for bowel movement outcomes and moderate certainty for the diarrhea outcome 3. Pooled analyses of patients treated for up to 104 weeks confirm linaclotide's overall favorable safety profile, with the vast majority of adverse events being mild to moderate and manageable 2.